by Netherlands Cancer Institute In the scientific journal Nature Medicine, researchers in the Netherlands report that neoadjuvant immunotherapy using a combination of two drugs (nivolumab and ipilimumab) is a feasible treatment for bladder cancer without harming the scheduled resection, and shows promising results. With this publication, bladder cancer is officially the third cancer type—following melanoma and colorectal cancer—for which researchers at the Netherlands Cancer Institute...
